20:28 , Nov 17, 2017 |  BC Week In Review  |  Financial News

Immuno-oncology play Arcus raises $107M

On Nov. 13, immuno-oncology company Arcus Biosciences (Hayward, Calif.) raised $107 million in a untranched series C round led by existing investor GV. New investors Wellington Management, EcoR1 Capital, BVF Partners, Decheng Capital, Hillhouse, Aisling...
00:01 , Nov 14, 2017 |  BC Extra  |  Financial News

Immuno-oncology play Arcus raises $107M

Immuno-oncology company Arcus Biosciences (Hayward, Calif.) raised $107 million in a untranched series C round led by existing investor GV. New investors Wellington Management, EcoR1 Capital, BVF Partners, Decheng Capital, Hillhouse, Aisling Capital and Leerink...
19:52 , Sep 22, 2017 |  BC Week In Review  |  Company News

Taiho gets option to Arcus' candidates

Cancer company Arcus Biosciences (Hayward, Calif.) granted Taiho Pharmaceutical Co. Ltd. (Tokyo, Japan) an option to develop and commercialize compounds...
20:01 , Aug 18, 2017 |  BC Week In Review  |  Company News

Arcus gets rights to PD-1 mAb from WuXi, Gloria

WuXi Biologics Inc. (HKSE:2269) and Harbin Gloria Pharmaceuticals Co. Ltd. (SZSE:002437) granted Arcus Biosciences (Hayward, Calif.) exclusive development and commercialization rights to PD-1 mAb GLS-010 (WBP3055). Arcus will gain rights in North America, Europe, Japan...
22:43 , Aug 17, 2017 |  BC Extra  |  Company News

Arcus gets rights to PD-1 mAb from WuXi, Gloria

WuXi Biologics Inc. (HKSE:2269) and Harbin Gloria Pharmaceuticals Co. Ltd. (SZSE:002437) granted Arcus Biosciences (Hayward, Calif.) exclusive development and commercialization rights to PD-1 mAb GLS-010 (WBP3055). Arcus will gain rights in North America, Europe, Japan...